Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma).
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Saracatinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 09 Jun 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 26 Oct 2012 Planned End Date changed from 1 Jan 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 07 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.